Mutations of the N-and K-ras genes are the most frequent genetic aberrations in acute myeloid leukemia (AML) and their detection in preleukemic conditions such as the myelodysplastic syndrome (MDS) suggests a role in the earliest phases of leukemogenesis. Despite these observations, little is known about the clinical importance of ras mutations in AML. We studied the clinical impact of ras mutations in 99 patients with de novo AML. All patients were treated in two prospective multicenter trials. The polymerase chain reaction was used to amplify areas surrounding the codons 12,13, and 61 of the three ras genes N-, K-, and H-ras from DNA from bone marrow cells. ras mutations were detected by an algorithm based on allelespecific oligonucleotide hybridization. Eighteen of 99 (1 8%) patients harbored mutations in either N-or K-ras. All of the observed mutations occurred in N-ras (N = 10) and K-ras (N = 5) or concurrently in both N-and K-ras (N = 3). There were no significant differences between ras-negative and EMBERS OF T H E ras proto-oncogenes have been and are among the most frequent genetic aberrations detected in human tumors. The three rus genes commonly involved, N-, K-, and H-ras, encode for closely related proteins, p2 l"", which localize to the inner plasma membrane and have intrinsic GTPase activity. Mutations in critical regions of the p2 1"" attenuate this GTPase activity, activate the oncoprotein, and lead to oncogenic transformation.
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EMBERS OF T H E ras proto-oncogenes have been
and are among the most frequent genetic aberrations detected in human tumors. The three rus genes commonly involved, N-, K-, and H-ras, encode for closely related proteins, p2 l"", which localize to the inner plasma membrane and have intrinsic GTPase activity. Mutations in critical regions of the p2 1"" attenuate this GTPase activity, activate the oncoprotein, and lead to oncogenic transformation.
With respect to hematologic malignancies, rus proto-oncogene mutations are the most commonly observed molecular alteration, with the reported incidence ranging from 20% to 30% in acute myeloid leukemia (AML).'. [3] [4] [5] [6] In AML and in the myelodysplastic syndromes (MDS), ras mutations have been associated with monocytic differentiat i~n .~.~. ' Studies in MDS, furthermore, suggest that ras mutations may encode for a higher proliferative activity of the affected These data would imply that biologic differences might be expected between patients with and without a ras mutation in de novo AML and that these biologic differences may lead to differences in response to chemotherapy and, potentially, to patient survival.
We sought to assess the role of ras proto-oncogene mutations with respect to their biologic and clinical relevance in adult AML. Using the polymerase chain reaction (PCR), we amplified rus sequences surrounding the critical codons 12, 13, and 61 in N-, K-, and H-rus from 99 patients with de novo AML enrolled in a national cooperative group's treatment studies. The mutations were then detected using oligonucleotides specific for the individual mutations with a sensitive PCR-based technique.'-" Analysis of survival data shows that mutations in the ras proto-oncogenes may portend a favorable prognosis in de novo AML. ras-positive patients according to age, sex. blood counts. cytogenetic abnormalities, or French-American-British classification. However, univariate analysis suggested a longer survival in ras-positive patients (P = .l 1 ). When adjusted for age, which was the most important factor affecting outcome, the presence of a f8S mutation emerged as a significant predictor for improved survival (P = .03) along with lower bone marrow blast counts (P = .02) and better cytogenetic category (P = .01). However, the presence of an aberrant ras allele was strongly correlated with lower bone marrow blast counts (P = .007). Thus, whether a mutation in the N-ras or K-ras proto-oncogenes directly affects treatment outcome or indirectly through an association with lower leukemic burden remains to be determined. Nevertheless, these findings counter the prevailing bias that oncogene mutations lead to more aggressive behavior in human malignancies.
MATERIALS AND METHODS
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ber 8525 (N = 86) and 8821 (N = 13). The genetic analyses were performed as part of CALGB companion protocols 836 l and 8765, which procured blood and bone marrow samples prospectively on patients entered on CALGB treatment studies. The diagnosis of AML was made with standard bone marrow and blood smears according to the French-American-British (FAB) classification. All slides were centrally reviewed. Patients with a history of myelodysplasia or having previously received chemotherapy were excluded from these studies. In 2 patients, the exact lineage of the leukemia could not be discerned on the initial morphologic examination; however, in both cases, cytogenetic and immunophenotyping data supported the diagnosis of a myeloid leukemia. In I case, cytogenetics [the presence oft(9; 1 l)] and immunophenotyping(CD1 Ib'. CD 14', CD I5+, and CD33+ staining) were consistent with AML. In thesecondcase,theimmunophenotyping(CDl3+,CDl4',CD15+, and CD33+ staining) was consistent with a myeloid leukemia. Thus, these patients were regrouped as AML unclassified (MO-AML).
Cytogenetics were performed in CALGB-approved institutional laboratories as part of a prognostic karyotype study. CALGB 846 l , and were centrally reviewed. Sixty-seven of the 99 patients had adequate cytogenetics and, of these, 30 cases (44%) had normal karyotypes and 56% were abnormal. In the overall group of 1.272 cases enrolled in the CALGB cytogenetics study, 56% of adequate cases were also abnormal. Thus, our cytogenetic distribution was representative of the larger group experience. Previous CALGB experience has shown that patients with t(8;2 I), abnormalitiesof 16q22, t( 1 S; 17). and patients with normal cytogenetics have a favorable prognosis as compared with those with other specific karyotypic abnormalities." Thus, for this present study. patients were categorized into a priori cytogenetic groups: better [including t(8;2 I). abnormalities of 16q22, t( This postremission chemotherapy program was repeated every 4 weeks for 4 months. After the initial 4 months of treatment, all patients received cytarabine (200 mg/m' on 5 consecutive days) and daunorubicin (45 mg/m') for another four cycles. Thereafter, the patients were followed-up writhout further therapy. CALGB 8821 was a study in which cytarabine (200 mg/m2 for 7 days) was combined with daunorubicin (45 mg/m' for 3 days) as induction and mitoxantrone/diaziquone, and etoposide/cyclophosphamide were then successively administered in two intensification course^.'^ Nine patients treated as part ofCALGB 882 I were ra. Y negative and 4 were rus positive. In both CALGB studies. the age requirement for eligibility was greater than I S years ofage and no upper age limit was imposed. The distribution of the vus-positive and m.r-negative cases did not difier amongst the various treatment groups ( P = .42). The median survival for all 99 patients was 1.2 years, with a median follow-up time of 4 years. No difference in survival was noted between patients entered on CALGB 8525 or 882 l ( P = .2S).
Blood and bone marrow cells were isolated on a Ficoll gradient. High molecular weight DNA was isolated using standard proced u r e~'~ and the molecular analysis was performed in a blinded fashion. Patient samples were identified randomly from the larger study group.
PC'R. PCR was performed with 200 ng DNA under standard conditions in 100 @L (50 mmol/L KCI, 10 mmol/L Tris Cl, pH 8.3. . Sequences surrounding N-. K-, and H-rus codons 12, 13, and 6 1 were amplified using the following protocol: cycle I , 94°C for 5 minutes, 55°C for 1 minute, and 72°C for 1 minute; cycles 2 through 35,94'C for 1 minute. 55°C for 1 minute, and 72°C for 1 minute. The oligonucleotide primers were used at 0.5 pmol/L and purchased from Clontech (Palo Alto, CA). In the first screen of the samples, PCR-amplified DNA was slot-blotted and probed with a mixture of up to six mutational specific oligonucleotides (Clontech) as described (probes for a total of 57 possible mutations were applied in each patient)." Each sample was investigated at least twice. After completing the molecular analysis on all 99 samples, the genomic DNA of positive samples was subjected to a second PCR amplification. Seven microliters of the PCR amplification was electrophoresed on a 3% NuSieve (FMC, Rockland, ME)/ I % agarose gel and hybridized with individual mutational specific probes after Southern transfer, as previously described.' ' This allele-specific oligonucleotide hybridization (ASOH) approach is sufficiently sensitive to detect one mutant allele in the presence of nine wild-type ras genes." Selected cases harboring ras mutations were subjected to further scrutiny by analyzing the peripheral blood DNA for the presence ofthe same mutation that was found in the bone marrow. In every case, the identical ray lesion was detected in both tissue sources. Four samples with ambiguous hybridization results were subjected to direct sequencing of the PCR products for sequence confirmation and, in each case, the sequence results corroborated the ASOH data."
Anul~:si.s of' clinical dutu. The molecular analyses were performed on the coded samples in a blinded fashion; the data from this analysis were then examined for association with the clinical parameters. Two end-points were used in the analysis: ( I ) survival time as defined by the time from registration on study to the date of death from any cause (patients still alive were censored at the date of last contact). and (2) remission duration as measured from the date ofCR to relapse or death. Patients still in continuous CR were censored at date of last follow-up. Sru/r.stical mc//zody. The following pretreatment patient characteristics were compared between the group of patients with a ras mutation and the group of patients without such mutations: age, sex, peripheral white blood cell count (WBC), platelet count, percentage of blasts in bone marrow, FAB classification, and cytogenetic classification [better: t(8;21), t( 15; 17), abnormalities of 16q22, or normal karyotype v worse: any other cytogenetic abnormality]. Analysis of frequencies was performed using the Fisher two-tailed exact test for 2 X 2 tables or the Pearson x2 test for larger tables. CR rates in the two rus groups were also compared using the Fisher exact test. Differences in median age for patient subgroups were tested with the Mann-Whitney statistic. Survival probabilities were estimated by the Kaplan-Meier method,16 and differences in the survival distributions between the ras-positive and rus-negative groups were tested with the log-rank statistic." The prognostic significance ofthe study variables, after adjusting for age, was assessed using the Cox proportional hazards model." Specifically. each study variable was considered individually in the presence of age, and the resulting increase in log-likelihood was tested for each variable by the likelihood ratio test. The natural logarithm ofthe WBC count and platelet count, denoted log[wbc], and log[plateletsl, respectively. were used to adjust for skewness in the distribution of these variables. Hazard estimates (and 95% confidence intervals) were obtained from the Cox model by exponentiating the regression coeflicients.
RESULTS
ras Mutations in 99 tered into study 882 1. From these groups, 122 patients were randomly selected for analysis: however, 23 ( 19%) were deemed ineligible because of a significant change in the initial diagnosis or inadequate blood or bone marrow samples. Ofthe 99 eligible patients, 86 were treated on CALGB 8525, and 13 were treated on CALGB 882 1. There were no apparent differences in outcome for our selected subgroups of patients when compared with the overall experience ofthe two respective treatment studies ( P = .92 in overall survival by treatment, P = .45 in time to failure by treatment).
Our strategy of screening a large number of samples was as follows. In the first analysis, a mixture of mutational-specific probes was applied for codons I2,13, and 6 I of each of the three rus genes using slot-blot analysis. An example of a typical slot-blot analysis for codon N-rus I2 is shown in Fig  1. Samples that were positive were reamplified from the original patient's DNA. These reamplified samples were transferred onto nylon filter paper using the Southern blot procedure3"*10 and then probed with individual mutationalspecific probes (Fig 2) . Occasional discrepancies (4 cases) between the two screens were then resolved with direct sequencing of the PCR products and, in all cases, the sequencingdata corroborated the ASOH results." In 6 patients, the rus mutation present in a bone marrow sample was further confirmed by the detection of the same mutation in the peripheral blood leukocytes. This algorithm effectively eliminated false-positives from the analysis. Using these procedures, 18 of 99 patients were found to harbor mutations in N-rus or K-rus. Ten patients had N-rus mutations only, 5 patients harbored K-rus mutations only, and 3 had two mutations (N-rus and K-rus) concurrently. No patient carried a mutation in H-rus. The percentage of blasts in the bone marrow was significantly lower in rus-positive than in the rus-negative patients ( P = .007). However, no other clinical parameter at presentation was associated with the presence of a rus mutation: specifically, age (median age of rus-positive group was 55.3 years and of the rus-negative group was 48.8 years: P = .82), FAB classification. cytogenetic grouping, blood counts, and sex (Table l) . Three rus-positive patients failed to respond to induction chemotherapy and. of the 15 rus-positive patients who achieved a CR (83% of 18 rus-positive patients), 4 remain in continuous CR. In the rus-negative group, 50 of 8 I patientsachieved CR (62%) and 19 patients remain in continuousCR.
AnuI.vsis ?~prC2qnoslic.fuclors. The median survival of our entire cohort of 99 patients was 1.2 years. Univariate Cox regression analysis identified age as the most significant factor associated with survival duration (P c .OOl; Table 2 ).
The median survival of patients under 40 years of age was 21 months. as compared with 12 months for patients between 40 and 59 years, and 3 months for those over 60 years of age. An increased peripheral leukocyte count was also associated with a poorer prognosis ( P = .02), as was a high platelet count at diagnosis ( P = .04). Interestingly, the presence of a mutant rus proto-oncogene appeared to be associated with a more favorable outcome, although the association was not statistically significant ( Table 2 ). The median survival of AML patients without rus mutations was 13 months. whereas that of patients with mutant rus genes was 19 months (log-rank test, P = .I3; Fig 3A) . No factor other than age, the WBC count, and the platelet count had a statistically significant association with survival when considered individually.
Because the most significant prognostic variable, age. may interact and obscure the impact of other factors on outcome, we sought to normalize the effect of age on the predictive value of the other four study variables using a multivariate Cox regression analysis. When age was taken into account, the presence of a rus mutation emerged as a significant predictor for better survival (P = .03), as did the cytogenetic status (P = .O 1) and the percentage of the bone marrow replaced by leukemic blasts (P = .02, Table 3 ). In this analysis, the hazard ratio is an estimate of the proportional increase in risk of death at any given time and age for a patient in a "worse" category relative to a patient in a "better" category. For patients without a rus mutation, the hazard ratio was 1.94 (95% confidence interval [CI], 1.01 to 3.76), indicating that their instantaneous risk of death is approximately twice that ofpatients of the same age harboring a rus mutation. However, the peripheral WBC count and the platelet count no longer affected survival (P = . l 1 and .18, respectively).
A better cytogenetic status and a lower percentage of blasts in the bone marrow were the only other factors that, after adjusting for age, remained associated with improved survival (P = .O I and P = .02, respectively; Table 3 ). Because the percentage of blasts in the bone marrow was statistically associated with the rus status ( Table l) , we sought to determine the relative importance of the bone marrow blast count and the rus status in predicting survival outcome using multivariate analysis. After adjusting for age and per- 81 (82) 30 (83) 30 (79) 21 (84) 41 (87) 40 (77) 24 (63) 20 (83) 37 (80) 42 (84) 1 1 (0.70-1.47)   1 .OO (0.63-1. 
60)
Variables significantly associated with survival are bolded.
Positive coefficients indicate better survival for the lower values of the continuous variables (eg, younger age is associated with better survival) and t For continuous variables, the hazard ratio indicates the relative increase in the risk of death for a unit change in the variable (eg, 1 year, 1 log [wbc]).
for the first category listed for the dichotomous variables (eg, presence of ras mutation is associated with better survival).
centage of bone marrow blasts (<60% and >60%), rus mutations did not appear to be associated with longer survival (P = .09). After adjustments for age and rus mutation status, the percentage of bone marrow blasts was also no longer associated with improved survival (P = . l l). Thus, though our data do not show a prognostic value for the rus mutation status independent of bone marrow blast percentage, larger numbers of patients will be needed to resolve this question. In seeking explanations for the improved survival of the rus-positive cases, we examined those parameters that may impact on overall survival. Neither complete remission rate (rus positive [83%] v rus negative [62%], P = .IO), event-free survival (P = .20), duration ofcomplete remission (P = .68, Fig 3B) , nor survival after relapse (P = .39) was statistically different between the two rus groups.
Associations with specific ras mutations. Of the 18 raspositive cases, 21 specific rus mutations were detected: 8 were in N-rus codon 12, 1 in N-rus codon 13, 4 in N-rus codon 6 1, 7 in K-rus codon 12, and l in K-ras codon 6 1 ( Table 4) . The most frequent base transition was a G + A exchange at codons 12 and 13 of N-and K-ras accounting for 13 ofthe 2 1 rus mutations. Analysis ofthe clinical factors associated with the specific rus mutations showed that, although patients with G + A transitions seemed to be older than those with other base changes, this difference was not statistically significant (excluding patient no. 69 with both types of base substitutions; median age, 55 years v 33 years, P = .13, Mann-Whitney test). Because all G + A changes occurred in codons 12 and 13, but not all codon 12 or 13 mutations were G + A mutations, we asked whether clinical associations could be better refined by examining the specific codons affected rather than the specific bases changed. In this analysis, a significant age difference was observed between patients with mutations in codons 12 or 13 (median age, 55.8 years) as compared with those with mutations in codon 6 1 (median age, 24.6; P = .02, Mann-Whitney test).
DISCUSSION
Mutations in the rus proto-oncogenes have been implicated in the genesis of AML and have been described in approximately 25% of cases. '*34~19, 20 This frequency makes aberrations in ras the most common molecular abnormality in this heterogeneous disease. Despite the prevalence of rus mutations, the clinical significance of such molecular aberrations in AML is unclear. To assess the impact of rus mutations on this disease, we sought to analyze a relatively uniform cohort of de novo AML patients who were diagnosed in a standard fashion and treated with intensive chemotherapeutic regimens.
In this study, we investigated the frequency and significance of ras mutations in 99 adult AML patients enrolled in two CALGB treatment protocols. The frequency of rus mutations in this prospective trial is in keeping with similar studies3? 18 of 99 patients ( 18%) harbored 2 1 aberrant ras alleles with 62% of these mutations in N-rus and 38% in Kras. We show that, after adjusting for age, the presence of any rus mutation appears to be a significant predictor of improved survival in AML. Other parameters previously shown to affect survival such as the percentage of blasts in the marrow and cytogenetic status also had impact on the clinical outcome. The cytogenetic status was not associated with the rus mutation status; however, patients with bone marrow blast content of less than 60% were more likely to be ras positive (P = .007). Multivariate analysis did not show that the ras mutation status significantly contributed to survival in addition to the percentage of blasts in the marrow and to age in this patient cohort (P = .09). Thus, the survival advantage in the ras mutation-positive cases may be caused by the lower leukemia burden treated. Moreover, although the median follow-up time of our study (4 years) is considerable, it remains possible that further late relapses in the rus-positive group will narrow the differences between the rus-positive and -negative populations. Thus, longer follow-up and larger patient numbers will be required to resolve these issues.
Many factors may contribute to the favorable outcome associated with ras mutations; however, our analysis did not uncover any specific factor that may explain this result. Nevertheless, although the CR rate was not significantly different between those with and without ras mutations, the CR rate in the rus-positive group was greater than that ofthe rus-negative group (83% v 62%, P = .IO). A similar finding was observed in an earlier study on 55 patients with de novo AML in that the CR rate in rus-positive patients was 63% versus 43% in rus-negative patients,6 leading to the speculaFor personal use only. on August 30, 2017 . by guest www.bloodjournal.org From precluding multivariate analysis. Furthermore, they were confounded by either incomplete ras analysis (eg, only the N-rus gene was assessed6); by nonuniform treatment regimens; or by including patients with A M L evolving from antecedent hematologic rnalignancie~.~ Our study differs in the extent of the ras analysis and the fact that all patients had de novo AML.
Other studies focusing on the clinical implication of rus mutations in lung adenocarcinomas*' and childhood acute lymphoblastic leukemias2* have found that patients harboring rus mutations were more likely to have a poor outcome compared with patients without rus mutations. The discrep For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From ancy between the ras effect in AML and these other malignancies may be caused by the innate biologic differences between the disease states. In experimental systems, a mutant ras allele can induce such disparate responses as transformation:' differentiati~n:~ or maturationz5 depending on the cellular context in which it is expressed. Furthermore, lung cancers, AML, and acute lymphocytic leukemia (ALL) are treated with different modalities and with different chemotherapeutic agents that may variably interact with a mutant ras protein. Thus, the impact of aberrant ras genes on clinical outcome is likely to be unique to the individual malignancy. In apparent contradiction to our findings, murine fibroblast (3T3) cells transfected with an activated ras gene have been reported to be more resistant to anthracyclines because of the augmented expression of the multidrug-resistance protein, MDRl .z6 However, this induction of anthracycline resistance was not seen by others in the identical sysFurthermore, the response of hematopoietic systems to the action of various oncogenes are frequently different from that ofNIH3T3 cells, as is seen in the disparate phenotypes of leukemic cell lines as compared with murine fibroblast cell lines when transfected with HER-2/nea2* Thus, any extrapolation of findings in 3T3 cells to primary leukemic cells should be performed with considerable caution. Several unexpected findings emerged from our study. A significant association was discovered between the presence of a ras mutation and a lower fraction of blasts in the bone marrow. Currently, we have no biologic explanation for this result. Nevertheless, this observation suggests that mutant ras-bearing leukemic cells may harbor different clinical properties. Furthermore, our analysis of the clinical factors associated with the specific ras mutations showed that patients with codons 12 and 13 were significantly older than those with codon 61 changes (median age, 56 years v 25 years). The frequency of specific base substitutions and their location may reflect exposure to certain mutagens. In ani- For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From mal models, carcinogens such as methyl-nitrosomethylurea and dimethylbenzanthracene induce specific ras mutations and can direct these mutations to either codon 12 or 6 1 .29, 30 Whether the association between age and the type of rus mutation is caused by specific exposure to different carcinogens or to differences in mechanisms of DNA repair is currently unclear.
Established prognostic indicators in de novo AML include age,3' cytogenetic abnormalities,I2 and the presence of dysmyelop~iesis.~~ With regard to genetic abnormalities, there are some cytogenetic aberrations that correlate with a poor (eg, trisomy 8, abnormal chromosome 5 or 7) and with a favorable prognosis [eg, t( 15; 17), t(8;2 l), abnormalities of 16q22, and normal karyotype]. Our analysis suggests that the presence of a mutation in rus portends a favorable prognosis in de novo acute myeloid leukemia, but that this improvement may be caused by a decreased leukemia burden. The relative importance of rus mutations and bone marrow blast counts in determining treatment outcome in AML will require an analysis of larger numbers of patients.
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